J
Johnson Neil W
Researcher at GlaxoSmithKline
Publications - 22
Citations - 1234
Johnson Neil W is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Cancer & Demethylase. The author has an hindex of 12, co-authored 22 publications receiving 1062 citations.
Papers
More filters
Journal ArticleDOI
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.
Helai P. Mohammad,Kimberly N. Smitheman,Chandrashekhar D. Kamat,David Soong,Kelly Federowicz,Glenn S. Van Aller,Jessica L. Schneck,Jeffrey D. Carson,Yan Liu,Michael Butticello,William G. Bonnette,Shelby A. Gorman,Yan Degenhardt,Yuchen Bai,Michael T. McCabe,Melissa B. Pappalardi,Kasparec Jiri,Xinrong Tian,Mcnulty Kenneth C,Rouse Meagan B,Patrick McDevitt,Thau F. Ho,Michelle Crouthamel,Timothy K. Hart,Nestor O. Concha,Charles F. McHugh,William H. Miller,Dashyant Dhanak,Peter J. Tummino,Christopher L. Carpenter,Johnson Neil W,Christine L. Hann,Ryan G. Kruger +32 more
TL;DR: A proliferation screen of cell lines representing a number of tumor types indicated that small cell lung carcinoma (SCLC) is sensitive to LSD1 inhibition, and a subset of SCLC lines and primary samples that undergo growth inhibition in response to GSK2879552 exhibit DNA hypomethylation of a signature set of probes, suggesting this may be used as a predictive biomarker of activity.
Journal ArticleDOI
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.
Sharad K. Verma,Xinrong Tian,Louis V. LaFrance,Celine Duquenne,Dominic Suarez,Kenneth A. Newlander,Stuart Paul Romeril,Joelle Lorraine Burgess,Seth W. Grant,Brackley James,Alan P. Graves,Daryl A. Scherzer,Art Shu,Christine Thompson,Heidi M. Ott,Glenn S. Van Aller,Carl A. Machutta,Elsie Diaz,Yong Jiang,Johnson Neil W,Steven D. Knight,Ryan G. Kruger,Michael T. McCabe,Dashyant Dhanak,Peter J. Tummino,Caretha L. Creasy,William H. Miller +26 more
TL;DR: This work has identified highly potent, selective, SAM-competitive, and cell-active EZH2 inhibitors, including GSK926 and GSK343, which are small molecule chemical tools that would be useful to further explore the biology of EZh2.
Journal ArticleDOI
Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing.
Sarah Gerhart,Wendy A. Kellner,Christine Thompson,Melissa B. Pappalardi,Xi-Ping Zhang,Rocio Montes de Oca,Elayne Penebre,Kenneth W. Duncan,Ann Boriack-Sjodin,BaoChau Le,Christina R. Majer,Michael T. McCabe,Christopher L. Carpenter,Johnson Neil W,Ryan G. Kruger,Olena Barbash +15 more
TL;DR: Broad anti-proliferative activity of potent, selective, reversible inhibitors of protein arginine methyltransferase 5 (PRMT5) including GSK3326595 is described in human cancer cell lines representing both hematologic and solid malignancies suggesting that the integrity of the p53-MDM4 regulatory axis defines a subset of patients that could benefit from treatment with GSK 3326595.
Patent
Diamino-pyrimidines and their use as angiogenesis inhibitors
Stanley D. Chamberlain,Mui Cheung,Holly Kathleen Emerson,Johnson Neil W,Kristen Elizabeth Nailor,Douglas M. Sammond,Marcus Semones +6 more
TL;DR: In this article, the authors described methods of making such benzimidazole derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.
Patent
Cyclopropylamines as lsd1 inhibitors
TL;DR: In this article, the use of cyclopropylamine derivatives for modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1), was described.